We sought to provide evidence-based guidelines for using progestogens for the prevention of preterm birth (PTB). METHODS: Relevant documents, in particular randomized trials, were identified using PubMed (US National Library of Medicine, 1983 through February 2012) publications, written in English, which evaluate the effectiveness of progestogens for prevention of PTB. Progesto gens evaluated were, in particular, vaginal progesterone and 17-alpha-hydroxy-progesterone caproate. Additionally, the Cochrane Library, organizational guidelines, and studies identified through review of the above were utilized to identify relevant articles. Data were evaluated according to population studied, with separate analyses for singleton vs multiple gestations, prior PTB, or short transvaginal ultrasound cervical length (CL), and combinations of these factors. Consistent with US Preventive Task Force suggestions, references were evaluated for quality based on the highest level of evidence, and recommendations were graded. RESULTS AND RECOMMENDATIONS: Summary of randomized studies indicates that in women with singleton gestations, no prior PTB, and short CL s20 mm at s24 weeks, vaginal progesterone, either 90-mg gel or 200-mg suppository, is associated with reduction in PTB and perinatal morbidity and mortality, and can be offered in these cases. The issue of universal CL screening of singleton gestations without prior PTB for the prevention of PTB remains an object of debate. CL screening in singleton gestations without prior PTB cannot yet be universally mandated. Nonetheless, implementation of such a screening strategy can be viewed as rea sonable, and can be considered by individual practitioners, following strict guidelines. In sin gleton gestations with prior PTB 20-36 6/7 weeks, 17-alpha-hydroxy-progesterone caproate 250 mg intramuscularly weekly, preferably starting at 16-20 weeks until 36 weeks, is recom mended. In these women with prior PTB, if the transvaginal ultrasound CL shortens to <25 mm at <24 weeks, cervical cerclage may be offered. Progestogens have not been associated with prevention of PTB in women who have in the current pregnancy multiple gestations, preterm labor, or preterm premature rupture of membranes. There is insufficient evidence to recom mend the use of progestogens in women with any of these risk factors, with or without a short CL.
Introduction
Progesterone was isolated and character ized in 1934, and its role in myometrial quiescence was first reported in 1954. 1, 2 From 2003 through 2011, several ran domized trials evaluating the effect of either 17-alpha-hydroxy-progesterone caproate (17P) given intramuscularly (IM) or natural progesterone given vag inally or orally for prevention of preterm birth (PTB) have been published. The term "progestogens" includes both vag inal progesterone and 17P.
Given this large amount of new im portant information, the scope of this ar ticle is to review the level-1 evidence (randomized controlled trials [RCTs] and metaanalyses of RCTs) evaluating the role of progestogens in the preven tion of PTB, and to provide clinicians with current recommendations for their use in possible clinical scenarios. Other publications have not addressed the to tality of this new information. [3] [4] [5] As 17P and vaginal progesterone may vary in their effect, 6 ,7 they will be ad dressed separately. The effects of inter ventions for reduction of PTB often vary by the population studied, and in partic ular by major risk factor categories for PTB. Major differences exist when ana lyzing effects of other interventions by number of fetuses (ie, singleton vs mul tiple gestations), prior PTB (vs not), and short cervical length (CL) on transvagi nal ultrasound (TVU) (vs not). 8 There fore data will be analyzed according to these major categories of risk.
What are the mechanism of action and safety data of progestogens? (Levels II and III)
The mechanisms of action and safety of progestogens are not the purpose of this review, and are discussed only briefly. While the exact mechanism of action of progestogens in preventing PTB is un known, several possibilities have been proposed (Table 1) . [9] [10] [11] [12] [13] [14] [15] [16] [17] In general, the evidence seems to favor 2 mechanisms: an antiinflammatory effect that counter acts the inflammatory process leading to PTB, and a local increase in progesterone in gestational tissues that counteracts the functional decrease in progesterone leading to PTB (Table 1) . [9] [10] [11] [12] [13] [14] [15] [16] [17] Regarding safety, several studies failed to detect any long-term effect from the intrauterine exposure of the fetus to pharmacologic progestogens, even when given in the first trimester. 18 Follow-up, at a mean of 4 years, of 278 children ran domized in the largest RCT evaluating 17P for prevention of recurrent PTB re vealed no differences in physical exami nation, health status, or performance (motor, problem solving, personal-so cial) compared to placebo. 19 Guideline   TABLE 1 Proposed mechanisms of action reported for progestogens to prevent preterm birth [9] [10] [11] [12] [13] [14] [15] [16] [17] Stimulate transcription of ZEB1 and ZEB2, which inhibit connexin 43 (gap-junction protein that helps synchronize contractile activity) and oxytocin-receptor gene 
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What is the evidence and recommendation for use of progestogens for prevention of PTB in singleton gestations with no prior PTB, with unknown CL? (Levels I and III)
17P
In 168 women in active military duty with only a 3% rate of prior PTB and unknown CL, 17P 1000 mg IM weekly starting at 16-20 weeks was not associ ated with any effect on the incidence of PTB or perinatal outcomes compared to placebo.
20
Vaginal progesterone
No RCT has evaluated the effect of vagi nal progesterone in this population.
In summary, there is insufficient evi dence to determine the impact on PTB of progestogens in singleton gestations with no history of PTB, and with un known or normal CL.
What is the evidence and recommendation for use of progestogens for prevention of PTB in singleton gestations with no prior PTB, but short CL? (Levels I, II, and III)
17P
It is particularly important to assess the effectiveness of progesterone in women without prior PTB, as most PTBs occur in this population. In 657 nulliparous women with singleton gestations with TVU CL s30 mm at 16-22 3/7 weeks, 17P 250 mg IM weekly through 36 weeks was associated with similar incidences of PTB <35 weeks (13.5% vs 16.1%; P = .35) and <37 weeks (25.1% vs 24.2%; P = .80) compared to placebo. 21 This RCT was stopped due to a planned in terim analysis that revealed further en rollment was statistically very unlikely to demonstrate a significant difference be tween the groups.
In 79 women with singleton pregnan cies (66% of whom had no prior PTB) with TVU CL <25 mm between 16-24 weeks, 17P was associated with similar rates of PTB and neonatal morbidity and mortality compared to cerclage. 22 Cer clage was significantly more effective than 17P at reducing the incidences of PTB <35 weeks and <37 weeks in the subgroup with TVU CL s15 mm. 22 This RCT was stopped before planned re cruitment was completed as the authors stated that "it had become impractical, unethical, and unreasonable to withhold progesterone from one study group." 23 A subgroup analysis of only women with out prior PTB confirmed significant benefit of progesterone in preventing PTB <34 weeks (RR, 0.54; 95% CI, 0.34 -0.88). 23 The prevalence of TVU CL s15 mm in the population screened for the study was 1.7%. Based on the fre quency of short TVU CL and effective ness for prevention of SPTB <34 weeks from the work of Fonseca et al, 23 the number of women needed to be screened with CL to prevent 1 SPTB <34 weeks is approximately 387, if all women with a CL s15 mm receive vaginal progester one. Once a TVU CL s15 mm is identi fied, the number needed to treat to pre vent 1 PTB <34 weeks is about 7.
22
Vaginal progesterone
In 458 women with singleton gesta tions and TVU CL 10-20 mm at 19-23 6/7 weeks, of whom about 84% had no prior PTB, vaginal progesterone 90-mg gel daily started at 20-23 6/7 weeks until 36 6/7 weeks was associated with a 45% significant reduction in PTB <33 weeks (9% vs 16%; RR, 0.55; 95% CI, 0.33-0.92), and a 43% significant reduction in composite neonatal morbidity and mor tality (8% vs 14%; RR, 0.57; 95% CI, 0.33-0.99). 24 The incidences of PTB <28 and <35 weeks, and respiratory distress syndrome (RDS), were also sig nificantly decreased. Analysis of only women without prior PTB confirmed significant benefit of progesterone in 
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www.AJOG.org preventing PTB <33 weeks (8% vs 15%; RR, 0.50; 95% CI, 0.27-0.90). 24 The prevalence of CL 10-20 mm was 2.3% in the population screened. The study en rolled patients in 44 centers in 10 coun tries (largest enrollment from United States, 46% of total), and the ethnic dis tribution of those included was about a third Caucasian, a third African Ameri can, and a third Asian. Protocol viola tions may have influenced the outcomes, and the study was both industry-and National Institutes of Health-spon sored. After evaluating data from this trial only, the Food and Drug Adminis tration (FDA) concluded that the study did not meet the statistical significance generally expected to support the ap proval of the product in the US market from a single trial. The FDA raised the issue of robustness in efficacy in the US subgroup as compared to overall efficacy in the trial, and stated that additional clinical work would be required to sup port the approval. 25 Based on the fre quency of short CL and effectiveness for prevention of PTB <33 weeks from this study, 24 the number of women needed to be screened with CL to prevent 1 PTB <33 weeks is approximately 604, if all women with a CL 10-20 mm receive vag inal progesterone. Once a TVU CL 10-20 mm is identified, the number needed to treat to prevent 1 PTB <33 weeks is about 14. The study did not address the management of women with a CL <10 mm.
In a metaanalysis, including 554 sin gleton gestations, with no prior PTB, and TVU CL s25 mm mostly <25 weeks, vaginal progesterone was associated with a significant reduction in PTB <33 weeks (RR, 0.60; 95% CI, 0.39 -0.92) and a nonsignificant reduction in com posite neonatal morbidity and mortality (RR, 0.70; 95% CI, 0.42-1.16). 26 Two cost-effectiveness analyses evalu ating universal CL screening in singleton gestations, to identify those with short CL eligible for vaginal progesterone, have been published so far. 27, 28 Both re ported that such a strategy would be cost-effective. In one study, compared to other managements, including no screening, universal sonographic screen ing of CL in singletons was predicted to result in a reduction of 95,920 PTBs <37 weeks annually in the United States, and was actually cost-saving (almost $13 bil lion saved). 27 Even varying the assump tions (eg, the cost of vaginal progester one or of TVU screening), universal screening was the preferred strategy 99% of the time. 27 The other cost-effectiveness analysis targeted women with singleton gestation without prior PTB. A strategy of univer sal screening with a single TVU CL at 18-24 weeks and treatment with vaginal progesterone if the CL was s1.5 cm resulted in >$12 million saved, 424 qualityadjusted life-years gained, and 22 neona tal deaths or long-term neurologic defi cits prevented for every 100,000 women screened compared with no screening. Even varying the assumptions over a wide range of possible values (eg, the cost of vaginal progesterone or of TVU screening), universal screening was costeffective >99% of the time. 28 This costeffectiveness analysis initially addressed only women with a TVU CL s1.5 mm. In an addendum, the authors mention that a reanalysis adding progesterone treatment for women with TVU CL be tween 1.6-2.5 mm did not change their conclusions, with the details of the re analysis not provided.
In summary, in women with singleton gestations, no prior SPTB, and short TVU CL, vaginal progesterone is associ ated with reduction in PTB and compos ite perinatal morbidity and mortality. Based on these results, 23, 24 if a TVU CL s20 mm is identified at s24 weeks, vag inal progesterone can be offered for pre vention of PTB. The 2 studies used dif ferent progesterone preparations and dosages. Vaginal progesterone 200-mg suppository was used in the trial for CL s15 mm, 23 and 90-mg gel for the trial for CL 10-20 mm. 24 There is insufficient evidence that any of the vaginal prepara tions or doses are superior, as they have not been compared. CL, cost, availabil ity, and other factors may influence pre ferred dosing. 27, 28 A decision of whether to institute a policy of universal screening for short cer vix with TVU in women with singleton gestations without prior PTB requires several careful considerations:
• The available trials have addressed ef ficacy of progesterone for women identified with a TVU short cervix. There are no data regarding effective ness of universal TVU screening for short cervix followed by vaginal pro gesterone for those with a short cervix, compared to no screening. The only evidence in favor of such an approach is based on cost-effectiveness analyses.
• It is possible that a proportion of women with a short cervix may be identified without a specific universal TVU screening. This may result in a lower than estimated added benefit of universal screening over current prac tice of visualization of the lower uter ine segment on all transabdominal ul trasound performed in the second trimester. Data are currently insuffi cient to suggest benefit, or harm, of transabdominal screening of CL for prevention of PTB using progesterone or any other intervention as therapy if a short CL is identified. Transabdom inal ultrasound may not detect 57% of women with a short TVU CL. 29 The randomized data on benefit from vag inal progesterone for women with short CL screened women utilizing TVU. 23, 24 • Universal screening approach may not produce the same results in practice as those in a controlled trial. This may be due to differences in population, logis tical differences in screening methods, stretching of the eligibility and man agement criteria (scope creep), and unintended consequences of universal screening. Performing multiple fol low-up scans, doing them outside of the studied gestational age (18-24 weeks), applying the treatment to women outside the studied CL range, or using other interventions for a short CL, such as bed rest or cerclage, may potentially result in adverse unin tended consequences. 
women with a CL <10 mm or between 20-25 mm. Neither trial included women with CL >20 mm, and there fore there is very limited evidence that vaginal progesterone is beneficial in these women. 23, 24, 26 It should be noted that only 1.7-2.3% of women were identified to have short CL in the 2 large trials published, 23, 24 but that the incidence of CL s20 mm at 22-24 weeks in the largest blinded US study was 5%. 30 The use of different progesterone formulations (90-mg gel and 200-mg suppository) between the 2 trials should also be taken into account. There is no evidence that the 2 preparations are interchangeable in that the one that was efficacious in the 10 -20 mm range would also be effica cious in those with a CL <10 mm. In a metaanalysis, both of these 2 prepara tions had similar significant efficacy. 26 • If an approach of universal screening is to be adopted, then TVU CL screening needs tobedonewithpropertechniqueandwith quality assurance to be effective.
• There may be lack of availability of this screening test in some geographic areas. 
Screening and treating abnormals is costeffective
Two cost-effectiveness articles published 27, 28 Yes, in fact cost-saving All of the above need to be taken into consideration when deciding on whether to change prenatal care for million of women by instituting universal screen ing with a single TVU assessment of CL at around 18-24 weeks in women with a singleton gestation without prior SPTB. On the other hand, TVU CL screening of singleton gestations does fulfill many cri teria for an effective screening test (Table  2) . [30] [31] [32] [33] A number of experts have recom mended TVU CL universal screen ing. [34] [35] [36] This is based mostly, in addition to what is listed on 
17P
In 43 women with mostly singleton ges tation (>90%) and either prior PTB or >1 prior spontaneous abortion, 17P 250 mg IM weekly started as soon as prena tal care began was associated with sig nificant reduction in PTB <37 weeks and perinatal mortality compared to placebo. 37 In 463 women with singleton gestation and prior SPTB at 20-36 6/7 weeks of a singleton gestation, compounded 17P 250 mg IM weekly started at 16-20 6/7 weeks was associated with reduction in the incidences of PTB <35 (RR, 0.66; 95% CI, 0.54 -0.81), PTB <37 and <32 weeks, and supplemental oxygen and in traventricular hemorrhage (IVH) com pared to placebo. 6 Based mostly on this clinical trial, 17P has been recommended for all women with prior SPTB 20-36 6/7 weeks. 3, 5 The estimated number of pre vented PTBs <37 weeks in the United States by this policy is about 9870 annually. 38 While the best evidence for efficacy is for 17P to be started <21 weeks, benefi cial effects have been reported when 17P is started by s27 weeks. 39 ,40 17P should not be stopped early (eg <32 weeks), as this is associated with increased inci dence of PTB. 41 
Vaginal progesterone
In 142 women with singleton gestations and mostly prior PTB (>90%), vaginal progesterone 100 mg nightly from 24-34 weeks was associated with significant re duction in the incidences of PTB <37 weeks (RR, 0.48; 95% CI, 0.25-0.96) and <34 weeks, as well as reduction in contrac tion frequency compared to placebo. 42 In 659 women with singleton gestation and prior SPTB 20-35 0/7 weeks, vaginal progesterone 90-mg gel every morning starting at 18-22 6/7 weeks and contin ued until 37 0/7 weeks was not associated with significantly different rates of PTB <37, 36, 33, or 29 weeks, or neonatal morbidity and mortality. 7 Several women screened for this trial were excluded be cause of short CL.
7
Effect of progesterone on CL In singleton gestations with prior PTB, 17P has not been associated with an ef fect on the development of short CL. 43 On the other hand, vaginal progesterone was associated with significant reduction in the incidence of short CL in women with singleton gestations and prior PTB. 16 
Oral progesterone
In 148 women with singleton gestation and prior SPTB 20-36 6/7 weeks, oral progesterone 100 mg twice a day was as sociated with significantly reduced rates of PTB <37 weeks and neonatal inten sive care unit admission compared to placebo. 44 In 33 women with singleton gestation and prior PTB 20-36 6/7 weeks, oral progesterone 400 mg daily was asso ciated with trend (but no significant dif ferences) for reduced rates of PTB <37 weeks (26% vs 57%; P = .15) and venti lator use (0% vs 21%; P = .07) compared to placebo. 45 In summary, in singleton gestation with prior SPTB, in which CL is un known, progestogen administration is beneficial in preventing PTB. Although we have limited data comparing the dif ferent preparations of progestogens, there is at present stronger evidence of effectiveness for 17P than for vaginal progesterone, based on the 2 largest tri als. 6, 7 Therefore, 17P 250 mg IM weekly starting at 16-20 weeks until 36 weeks should be recommended to women with singleton gestations and prior SPTB 20-36 6/7 weeks. In cases in which 17P is unavailable, other progesterone prepa rations may be considered.
42
What is the evidence and recommendation for use of progestogens for prevention of PTB in singleton gestations with prior PTB, and short CL? (Levels I, II, and III)
17P
There are no RCTs evaluating the effec tiveness of 17P compared to placebo in women with singleton gestations, prior PTB, and short CL. In this population, 17P has only been evaluated as an ad junct or an alternative to cervical cerclage.
In singleton gestations with prior SPTB and a short TVU CL <25 mm at <23 weeks, 17P was associated with sta tistically significant decrease in PTB <24 weeks and perinatal death in women not receiving cerclage in a secondary analysis of a cerclage trial. 46 Beneficial effects of 17P were noted primarily for women with CL 15-24.9 mm, while they were nonsignificant for women with CL <15 mm. Overall, women with a CL <25 mm www.AJOG.org SMFM Clinical Guideline had a 34% risk of PTB <32 weeks if they received neither 17P nor cerclage, 25% if they received cerclage, 21% if they re ceived 17P, and 17% if they received both. 46 While these results were not sta tistically significant, they suggest that further research is needed to evaluate the relationship and possible cumulative beneficial effect of progesterone and cerclage.
In a randomized trial that did not recruit the planned sample size, 17P had similar effects compared to cerclage in preventing PTB in women with a TVU CL <25 mm, but cerclage was more beneficial in women with CL <15 mm. 22 While cerclage seems to be more efficacious (lower RRs) for CL on the lower end of the range, 47, 48 proges terone seems to be most efficacious for moderately short CL. 23, 24, 26 
FIGURE
Algorithm for use of progestogens in prevention of PTB in clinical care
Vaginal progesterone
In a secondary analysis of an RCT 7 eval uating just the 46 singleton gestations with prior SPTB <35 weeks and short TVU CL <28 mm at 18-22 6/7 weeks, vaginal progesterone 90-mg gel daily started at 18-23 6/7 weeks until 37 weeks was associated with significant decreases in the rates of both PTB <32 weeks and neonatal intensive care unit admission compared to placebo. 49 In 71 singleton gestations with prior PTB, vaginal progesterone 100-mg sup positories daily between 24-34 weeks was associated with significant reduction in incidences of PTB <37 weeks (24% vs 50%; odds ratio [OR], 3.11; 95% CI, 1.13-8.53) and <34 weeks (5.4% vs 26.5%; OR, 6.30; 95% CI, 1.25-31.70) compared to placebo. 50 In a metaanalysis, including 169 sin gleton gestations with prior PTB and TVU CL s25 mm mostly <25 weeks, vaginal progesterone was associated with a significant reduction in PTB <33 weeks (RR, 0.54; 95% CI, 0.30 -0.98) and in composite neonatal morbidity and mortality (RR, 0.41; 95% CI, 0.17-0.98). 26 Based on the pooled results of 5 clini cal trials, in 504 singleton pregnancies with prior SPTB at <34 weeks and TVU CL <25 mm at <24 weeks' gestation, cerclage was associated with a significant 30% reduction in the risk of PTB <35 weeks (28% vs 41%; RR, 0.70; 95% CI, 0.55-0.89) and a 36% reduction in com posite perinatal mortality and morbidity (16% vs 25%; RR, 0.64; 95% CI, 0.45-0.91). 8 Therefore screening women with singleton gestations with prior SPTB with TVU CL starting usually at 16 weeks and every 2 weeks until 23 weeks is sug gested, so that cerclage can be offered for those who develop a TVU CL <25 mm. As the vast majority of women in this metaanalysis and its included random ized trials did not receive 17P, there is insufficient evidence to determine if the concurrent use of progesterone and cerclage offers an additive effect in reducing the risk of PTB in this group of women with prior PTB. 46 Therefore, the optimal management of the patient with progres sive cervical shortening despite proges terone therapy remains uncertain.
In summary, 17P should be recom mended to women with prior SPTB starting at 16 weeks, as described above. If the cervix shortens <25 mm by TVU <24 weeks in such a woman with single ton gestation and prior SPTB, there is in sufficient evidence to assess efficacy of a different progesterone therapy, and therefore it is reasonable to continue 17P SMFM Clinical Guideline www.AJOG.org until 36 weeks, and to offer cervical cer clage (Figure) . 17P, 17-alpha-hydroxy-progesterone caproate; CL, cervical length; IM, intramuscularly; PPROM, preterm premature rupture of membranes; PTL, preterm labor; SPTB, spontaneous preterm birth; TVU, transvaginal ultrasound.
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What is the evidence and recommendation for use of progestogens for prevention of PTB in multiple gestations, and unknown or normal CL? (Levels I and III)
17P
In 77 women with twin gestation, 17P 250 mg IM weekly from 28-33 weeks was not associated with any effect on PTB rates or perinatal morbidity and mortal ity compared to placebo.
51
In 655 women with dichorionic (DC) twin gestation, of whom <10% had prior PTB, 17P 250 mg IM weekly start ing at 16-20 weeks and ending at 35 weeks was not associated with any effect on PTB rates or perinatal morbidity and mortality in a National Institute of Child Health and Human Developmentsponsored RCT compared to placebo. 52 In 30 women with twin gestation, of whom 27% had a prior PTB, 17P 250 mg IM weekly starting at 20-30 weeks and ending at 34 weeks was associated with similar incidences of PTB <35 weeks and <30 weeks, as well as similar rates of neonatal morbidity and mortality com pared to placebo. CL was not reported. 10 In 240 women with DC twin gestation, 17P 250 mg IM weekly starting at 16-24 weeks until 34 weeks was associated with similar incidences of PTB and neonatal morbidity compared to placebo. weeks was not associated with effects on incidence of PTB or perinatal morbidity and mortality compared to placebo. 54, 55 Vaginal progesterone In 500 women with twin gestation, vaginal progesterone 90 mg daily starting at 24 weeks and continued for at least 10 weeks was not associated with significant effects in inci dences of PTB or perinatal morbidity and mortality compared to placebo.
56
In 677 women with diamniotic twin ges tation, vaginal progesterone 200-mg pessar ies starting at 20-24 weeks until 34 weeks werenotassociatedwithsignificanteffectson incidences of PTB or perinatal complications compared to placebo. 57 In 67 twin gestations, vaginal proges terone 100-mg suppositories daily be tween 24-34 weeks were associated with significant reduction in incidences of PTB <37 weeks (51% vs 79%; OR, 3.48; 95% CI, 1.16 -10.46) but not <34 weeks (10% vs 25%; OR, 2.90; 95% CI, 0.76 -11.20) compared to placebo. 49 No RCT has yet been reported on the ef fect of vaginal progesterone on triplet gesta tions.
MAY 2012
In summary, the evidence does not sup port the use of any type of progestogen for prevention of PTB in multiple gestations with unknown CL. In women with prior SPTB,andacurrentmultiplegestation,some experts have suggested the use of 17P starting at16weeksbasedonthehistoricriskfactor, 58 but there is insufficient evidence to make this a recommendation.
What is the evidence and recommendation for use of progestogens for prevention of PTB in multiple gestations, and short CL? (Levels I and III)
17P
In a secondary analysis of a trial involv ing women with DC twin gestation, 52 women, of whom 18.5% had prior PTB, were identified to have a TVU CL of s35 mm (25th percentile) between 16-20 weeks. 17P 250 mg IM weekly starting at 16-20 weeks and ending at 35 weeks was associated with similar incidences of PTB <35 weeks (64% vs 46%; P = .18) compared to placebo.
59
Vaginal progesterone
In a secondary analysis of a trial involv ing women with diamniotic twin gesta tion, 47 women, of whom 9% had prior PTB, were identified to have TVU CL s30 mm between 20-24 weeks. Vaginal progesterone 200-mg pessaries starting at 20-24 weeks until 34 weeks were not associated with an effect on PTB <34 weeks (29% vs 40%; RR, 0.63; 95% CI, 0.18 -2.23) compared to placebo. 60 In a metaanalysis, including 52 twin gestations found to have a TVU CL <25 mm at s24 weeks, vaginal progesterone was associated with similar incidence of PTB <33 weeks (30% vs 45%; RR, 0.70; 95% CI, 0.34 -1.44) and <35 weeks (52% vs 62%; RR, 0.91; 95% CI, 0.57-1.46), but a significant reduction in com posite neonatal morbidity and mortality (24% vs 40%; RR, 0.56; 95% CI, 0.30 -0.97) compared to placebo. 26 In summary, there is insufficient evi dence to assess the effect of progestogens in women with both multiple gestation and short CL.
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What is the evidence and recommendation for use of progestogens for prevention of PTB in preterm labor? (Levels I, II, and III)
Primary tocolysis
In 57 women admitted between 13-36 weeks with contractions, progesterone 400 mg orally once was associated with a significant decreaseinthefrequencyofcontractions,but no PTB or neonatal outcomes were reported compared to placebo. 61 
Adjunctive tocolysis
In 44 women with mostly singleton gestations (>90%) and threatened preterm labor (PTL) at <35 weeks treated with ritodrine, natural progesterone 400 mg orally every 6 hours X 24 hours (then 400 mg every 8 hours for next 24 hours, and then 300 mg every 8 hours onward) was associated with similar rates of PTB, but with lower total dose of ritodrine administered and shorter maternal hospital stay compared to placebo. 62 
Maintenance tocolysis
17P. In 60 women with singleton ges tation still pregnant after successful to colysis for PTL, 17P 341 mg twice weekly started at 25-33 6/7 weeks until 36 weeks was associated with signifi cant reduction in the incidence of PTB <37 weeks (but not 35 weeks) and of risk of cervical shortening compared to no such treatment. 63 In 188 women with singleton gestations still pregnant after successful tocolysis for PTL, 17P 500 mg IM twice weekly started at 24-31 6/7 weeks until 36 weeks was as sociated with similar incidences of PTB <37, <34, and <32 weeks, and of perina tal morbidity and mortality compared to no such treatment. 64 Vaginal progesterone. In 70 women with singleton gestation still pregnant after suc cessful tocolysis for PTL, vaginal progester one 400 mg daily until delivery was associ ated with longer latency until delivery, later gestational age at delivery (PTB was not re ported), and RDS compared to no such treatment. 65 In summary, there is currently insuffi cient evidence to recommend progesto gens for primary, adjunctive, or mainte nance tocolysis.
What is the evidence and recommendation for use of progestogens for prevention of PTB in preterm premature rupture of membranes? (Levels I and III)
17P
In 69 women with singleton gestations and preterm premature rupture of mem branes (PPROM) at 24-30 weeks, 17P 250 mg IM is associated with no effect on interval to delivery, gestational age at de livery, or neonatal mortality and mor bidity compared to placebo.
11
Vaginal progesterone
In summary, there is insufficient evi dence to assess effect of progesterone in women with PPROM. In a woman who has been receiving 17P for prior SPTB, in the absence of evidence to the contrary, it is reasonable to continue 17P once mem branes have ruptured.
Conclusions
Assessment of efficacy of progestogens for prevention of PTB should be done separately for each type of progestogens, with vaginal and IM routes of administration the most studied types (Table 3) . Efficacy probably varies also depending on each different risk factor. In addition, dose, gestational age at initiation and termination, compliance, and other issues are factors that influence efficacy of progestogens for prevention of PTB. Therefore, singleton vs multiple gestation, history (eg, prior PTB), short TVU CL (and degree of) or not, asymptomatic vs PTL and PPROM, etc, are all factors that should be considered, as progestogens have different effects in populations with any one (or com bination of) risk factor. Several metaanalyses have been published, 4,66-68 but they either do not evaluate these studies according to the different populations just mentioned, or soon become out of date because of publica tions of new RCTs. Recommendations were graded in the following categories:
RECOMMENDATIONS
Level A The recommendation is based on good and consistent scientific evidence.
Level B
The recommendation is based on limited or inconsistent scientific evidence.
Level C
The recommendation is based on expert opinion or consensus. 
